Lipocine Inc. 8-K

What Happened

• Lipocine Inc. (LPCN) filed an 8-K on February 18, 2026 reporting a preliminary, unaudited cash and cash equivalents balance of approximately $19.0 million as of January 31, 2026. The company noted this estimate is subject to financial close procedures and has not been audited or reviewed by independent accountants.
• In the same filing, Lipocine issued a press release (furnished as Exhibit 99.1) announcing the last patient last visit (LPLV) in its pivotal Phase 3 clinical trial of LPCN‑1154 for postpartum depression (PPD).

Key Details

• Preliminary cash and cash equivalents: approximately $19 million as of January 31, 2026 (unaudited, preliminary).
• Filing date / press release: February 18, 2026; LPLV announced for the pivotal Phase 3 trial of LPCN‑1154 (PPD).
• The cash estimate is subject to completion of financial closing procedures and has not been audited, reviewed, compiled, or otherwise verified by independent accountants.
• The press release reporting LPLV is included as Exhibit 99.1 to the 8-K.

Why It Matters

• Cash position: The ~ $19M preliminary cash balance gives a snapshot of Lipocine’s near-term liquidity; investors can use this to assess runway and funding needs but should note the figure is unaudited and preliminary.
• Clinical milestone: LPLV is an important non‑clinical outcome indicating trial enrollment/monitoring is complete, which typically precedes data analysis and potential topline results—this can be a catalyst for future updates.
• Caution: The company explicitly warns these financial figures are preliminary and not a substitute for audited GAAP statements; no trial results or timing for topline data were provided in the 8-K.